Skip to content

Nasdaq · CIK 0001858848

TNYA Tenaya Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing 31 d ago. Close $0.58 on Oct 9, 2026, +9% from the 52-week low and -72% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company

Price and insider trades, last year

TNYAOct 9, 2026 · close 0.58

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Tenaya Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
33WeakFaraz Ali
Chief Executive Officer
sell
$4,158
3,126 shares
-1%+225% from low-67% from high
23WeakTomohiro Higa
SVP, Finance
sell
$1,818
1,367 shares
-1%+225% from low-67% from high
40ModerateFaraz Ali
Chief Executive Officer
sell
$18k
14,533 shares
-5%+225% from low-67% from high
30WeakTomohiro Higa
SVP, Finance
sell
$3,711
2,962 shares
-3%+225% from low-67% from high
30WeakWhittemore Tingley
Chief Medical Officer
sell
$6,331
5,053 shares
-3%+225% from low-67% from high
40ModerateFaraz Ali
Chief Executive Officer
sell
$1,412
3,189 shares
-1%+16% from low-88% from high
30WeakTomohiro Higa
SVP, Finance
sell
$615
1,390 shares
-1%+16% from low-88% from high
30WeakWhittemore Tingley
Chief Medical Officer
sell
$1,300
2,937 shares
-2%+16% from low-88% from high
33WeakFaraz Ali
Chief Executive Officer
sell
$5,245
9,741 shares
-3%-
23WeakTomohiro Higa
SVP, Finance
sell
$1,336
2,482 shares
-2%-
50ModerateColumn Group III Gp, LP
owner
buy
$25M
35,714,284 shares
+263%-
58ModerateDavid Goeddel V
director, owner
buy
$25M
35,714,284 shares
+263%-
15WeakChihiro Saito
SVP, Accounting and Fin. Ops.
sell
$4,787
2,258 shares
-4%-

Transactions

The last 55 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 10, 2026Whittemore Tingley
Chief Medical Officer
AGrant or award
Common Stock
+49,000$0.00$0263,07331 d ago
Sep 10, 2026Faraz Ali
Chief Executive Officer
AGrant or award
Common Stock
+122,000$0.00$0539,78231 d ago
Sep 10, 2026Faraz Ali
Chief Executive Officer
AGrant or award
Stock Option (Right to buy)derivative
+732,500$0.00$0732,50031 d ago
Sep 10, 2026Whittemore Tingley
Chief Medical Officer
AGrant or award
Stock Option (Right to buy)derivative
+293,000$0.00$0293,00031 d ago
Nov 17, 2025Faraz Ali
Chief Executive Officer
SOpen-market sale
Common Stock
-3,126$1.33$4,158299,666Nov 17, 2025
Nov 17, 2025Tomohiro Higa
SVP, Finance
SOpen-market sale
Common Stock
-1,367$1.33$1,81893,971Nov 17, 2025
Aug 18, 2025Faraz Ali
Chief Executive Officer
SOpen-market sale
Common Stock
-5,720$1.25$7,167311,605Aug 18, 2025
Aug 18, 2025Tomohiro Higa
SVP, Finance
SOpen-market sale
Common Stock
-523$1.25$65597,777Aug 18, 2025
Aug 18, 2025Whittemore Tingley
Chief Medical Officer
SOpen-market sale
Common Stock
-1,608$1.25$2,015176,248Aug 18, 2025
Aug 18, 2025Faraz Ali
Chief Executive Officer
SOpen-market sale
Common Stock
-3,893$1.25$4,878307,712Aug 18, 2025
Aug 18, 2025Tomohiro Higa
SVP, Finance
SOpen-market sale
Common Stock
-717$1.25$89897,060Aug 18, 2025
Aug 18, 2025Whittemore Tingley
Chief Medical Officer
SOpen-market sale
Common Stock
-1,608$1.25$2,015174,640Aug 18, 2025
Aug 18, 2025Whittemore Tingley
Chief Medical Officer
SOpen-market sale
Common Stock
-1,837$1.25$2,302172,803Aug 18, 2025
Aug 18, 2025Tomohiro Higa
SVP, Finance
SOpen-market sale
Common Stock
-1,722$1.25$2,15895,338Aug 18, 2025
Aug 18, 2025Faraz Ali
Chief Executive Officer
SOpen-market sale
Common Stock
-4,920$1.25$6,165302,792Aug 18, 2025
May 29, 2025Amy L. Burroughs
director
AGrant or award
Stock Option (Right to buy)derivative
+107,400$0.00$0107,400May 30, 2025
May 29, 2025David Goeddel V
director, owner
AGrant or award
Stock Option (Right to buy)derivative
+107,400$0.00$0107,400May 30, 2025
May 29, 2025June Lee
director
AGrant or award
Stock Option (Right to buy)derivative
+107,400$0.00$0107,400May 30, 2025
May 29, 2025Karah Herdman Parschauer
director
AGrant or award
Stock Option (Right to buy)derivative
+107,400$0.00$0107,400May 30, 2025
May 29, 2025Deepak Srivastava
director
AGrant or award
Stock Option (Right to buy)derivative
+107,400$0.00$0107,400May 30, 2025
May 29, 2025Catherine Stehman-Breen
director
AGrant or award
Stock Option (Right to buy)derivative
+107,400$0.00$0107,400May 30, 2025
May 29, 2025R Sanders Williams
director
AGrant or award
Stock Option (Right to buy)derivative
+107,400$0.00$0107,400May 30, 2025
May 29, 2025Jeffrey T. Walsh
director
AGrant or award
Stock Option (Right to buy)derivative
+107,400$0.00$0107,400May 30, 2025
May 16, 2025Faraz Ali
Chief Executive Officer
SOpen-market sale
Common Stock
-3,189$0.44$1,412317,325May 16, 2025
May 16, 2025Tomohiro Higa
SVP, Finance
SOpen-market sale
Common Stock
-1,390$0.44$61598,300May 16, 2025
May 16, 2025Whittemore Tingley
Chief Medical Officer
SOpen-market sale
Common Stock
-2,937$0.44$1,300171,856May 16, 2025
Mar 10, 2025Faraz Ali
Chief Executive Officer
SOpen-market sale
Common Stock
-5,794$0.54$3,119324,461Mar 10, 2025
Mar 10, 2025Tomohiro Higa
SVP, Finance
SOpen-market sale
Common Stock
-1,017$0.54$548101,155Mar 10, 2025
Mar 10, 2025Faraz Ali
Chief Executive Officer
SOpen-market sale
Common Stock
-3,947$0.54$2,125320,514Mar 10, 2025
Mar 10, 2025Tomohiro Higa
SVP, Finance
SOpen-market sale
Common Stock
-620$0.54$334100,535Mar 10, 2025
Mar 10, 2025Tomohiro Higa
SVP, Finance
SOpen-market sale
Common Stock
-845$0.54$45599,690Mar 10, 2025
Mar 5, 2025Column Group III Gp, LP
owner
POpen-market purchase
Common Stockindirect: See Footnote
+35,714,284$0.70$25M49,313,559Mar 7, 2025
Mar 5, 2025David Goeddel V
director, owner
POpen-market purchase
Common Stockindirect: See Footnote
+35,714,284$0.70$25M49,313,559Mar 7, 2025
Mar 5, 2025Column Group III Gp, LP
owner
POpen-market purchase
Series A Warrant (right to buy)derivativeindirect: See Footnote
+35,714,284--35,714,284Mar 7, 2025
Mar 5, 2025David Goeddel V
director, owner
POpen-market purchase
Series A Warrant (right to buy)derivativeindirect: See Footnote
+35,714,284--35,714,284Mar 7, 2025
Mar 5, 2025Column Group III Gp, LP
owner
POpen-market purchase
Series B Warrant (right to buy)derivativeindirect: See Footnote
+17,857,142--17,857,142Mar 7, 2025
Mar 5, 2025David Goeddel V
director, owner
POpen-market purchase
Series B Warrant (right to buy)derivativeindirect: See Footnote
+17,857,142--17,857,142Mar 7, 2025
Feb 6, 2025Faraz Ali
Chief Executive Officer
AGrant or award
Common Stock
+107,500$0.00$0295,831Feb 7, 2025
Feb 6, 2025Faraz Ali
Chief Executive Officer
AGrant or award
Common Stock
+34,424$0.00$0330,255Feb 7, 2025
Feb 6, 2025Faraz Ali
Chief Executive Officer
AGrant or award
Stock Option (Right to buy)derivative
+650,000$0.00$0650,000Feb 7, 2025
Feb 6, 2025Faraz Ali
Chief Executive Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-353,271--0Feb 7, 2025
Feb 6, 2025Faraz Ali
Chief Executive Officer
AGrant or award
Stock Option (Right to Buy)derivative
+353,271--353,271Feb 7, 2025
Feb 6, 2025Faraz Ali
Chief Executive Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-161,214--0Feb 7, 2025
Feb 6, 2025Faraz Ali
Chief Executive Officer
AGrant or award
Stock Option (Right to Buy)derivative
+161,214--161,214Feb 7, 2025
Feb 6, 2025Faraz Ali
Chief Executive Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-401,390--0Feb 7, 2025
Feb 6, 2025Faraz Ali
Chief Executive Officer
AGrant or award
Stock Option (Right to Buy)derivative
+401,390--401,390Feb 7, 2025
Nov 18, 2024Chihiro Saito
SVP, Accounting and Fin. Ops.
SOpen-market sale
Common Stock
-2,258$2.12$4,78760,983Nov 18, 2024
Oct 18, 2024Amy L. Burroughs
director
AGrant or award
Stock Option (Right to buy)derivative
+34,000$0.00$034,000Oct 21, 2024
Oct 18, 2024David Goeddel V
director, owner
AGrant or award
Stock Option (Right to buy)derivative
+34,000$0.00$034,000Oct 21, 2024
Oct 18, 2024June Lee
director
AGrant or award
Stock Option (Right to buy)derivative
+34,000$0.00$034,000Oct 21, 2024
Oct 18, 2024Karah Herdman Parschauer
director
AGrant or award
Stock Option (Right to buy)derivative
+34,000$0.00$034,000Oct 21, 2024
Oct 18, 2024Deepak Srivastava
director
AGrant or award
Stock Option (Right to buy)derivative
+34,000$0.00$034,000Oct 21, 2024
Oct 18, 2024Catherine Stehman-Breen
director
AGrant or award
Stock Option (Right to buy)derivative
+34,000$0.00$034,000Oct 21, 2024
Oct 18, 2024R Sanders Williams
director
AGrant or award
Stock Option (Right to buy)derivative
+34,000$0.00$034,000Oct 21, 2024
Oct 18, 2024Jeffrey T. Walsh
director
AGrant or award
Stock Option (Right to buy)derivative
+34,000$0.00$034,000Oct 21, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

TNYA insider trading: Tenaya Therapeutics, Inc. | InsiderTell